Cornell University researchers engineered the BEAM system, a continuously oxygenated macroencapsulation device that supports high-density packing and delivery of insulin-secreting cells without immunosuppression. Published in Nature Communications, this approach addresses oxygen deprivation issues common in cell transplantation therapies for type 1 diabetes. The device maintains implanted cells’ viability and function by integrating oxygen generation, potentially revolutionizing long-term cell replacement therapies by circumventing immune challenges.